Official Title
JNJ-53718678 RSV Pre-Approval Access_Single Patient Access (SPR) for Patients Diagnosed With RSV
Brief Summary

The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus [RSV] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.

Individual Patients
Respiratory Syncytial Virus

Drug: JNJ-53718678
JNJ-53718678 will be administered as directed by treating physician.


1-800-JANSSEN (1-800-526-7736)

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

Janssen Sciences Ireland UC
NCT Number